Companies: 10,795·Total market cap: $144.5T
Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

IONSNASDAQHealthcare● Active
$74.48
$-0.65(-0.87%)
Market Cap$12.3B
P/E Ratio
52W High$86.74
52W Low$34.78
Overview

Ionis Pharmaceuticals, Inc. (IONS) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · IONS · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1.99ions eps ttm · ions earnings per shareEarnings history
PE Ratio (TTM)ions pe ratio ttm · ions price to earningsPE Ratio deep dive
Revenue (TTM)$1.1Bions revenue ttm · ions annual revenueFull revenue history
Dividend YieldNo Dividenddoes ions pay dividends · ions dividend yieldDividend history
Shares Outstanding160.0Mions shares outstanding · ions floatShares outstanding history
Next EarningsAug 5, 2026Est.ions earnings date · ions next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$944.0M▲ +33.87% YoY
202320242025
ionis pharmaceuticals, inc. revenue · ions revenue 2025
FY 2025Net Income-$381.0M▲ +16.06% YoY
202320242025
ionis pharmaceuticals, inc. net income · ions profit 2025
FY 2025EPS$-2.38▲ +21.71% YoY
202320242025
ions eps · ionis pharmaceuticals, inc. earnings per share 2025
TTM:Revenue: $1.06BNet Income: -$326.6MEPS: $-1.99View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy32 analystsis ions a buy · ions analyst rating
Strong Buy
1
Buy
19
Hold
12
Sell
0
Strong Sell
0
12-Month Price Target
$87.00Low
$74.48Current
$107.27Avg Target44.03% upside
$130.00High
ions price target · ions 12 month forecast

Total: 32 · Buy rate: 62.5%

The IONS analyst consensus is Buy, based on ratings from 32 Wall Street analysts over the past 3 months. The average 12-month price target is $107.27, representing +44.03% upside from the current price of $74.48.

Stock Performance

Full History
1D-0.87%
1W+2.48%
1M-1.62%
3M+0.59%
YTD-5.85%
1Y+102.61%
5Y+101.90%

About Ionis Pharmaceuticals, Inc.

CEOBrett Monia
IPO DateMay 17, 1991
Employees1,069
CountryUS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSED…

what is ionis pharmaceuticals, inc. · ions stock overview · ionis pharmaceuticals, inc. company profile · who is ionis pharmaceuticals, inc. ceo · ions NASDAQ · ionis pharmaceuticals, inc. headquarters · ionis pharmaceuticals, inc. business segments

About Stock Overview & Key Data

Ionis Pharmaceuticals, Inc. (IONS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 17, 1991. As of the latest trading session, IONS stock price is $74.48, with a market capitalization of $12.3B. The stock has returned +102.61% over the past 12 months and -5.85% year-to-date.

According to 32 Wall Street analysts, the consensus rating for Ionis Pharmaceuticals, Inc. stock is Buy, with an average 12-month price target of $107.27. In fiscal year 2025, Ionis Pharmaceuticals, Inc. reported revenue of $944.0M and net income of -$381.0M. For detailed data — including Ionis Pharmaceuticals, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Ionis Pharmaceuticals, Inc. (IONS) stock price is $74.48. The stock is traded on NASDAQ under the ticker symbol IONS. The 52-week range is $34.78 – $86.74.

IONS stock priceIONS quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice